Drug Profile
Mercaptamine - NovaBiotics
Alternative Names: Cysteamine - NovaBiotics; Lynovex; Mufrosyn®; NM 001 - NovaBiotics; NM-002; NM003; NylexaLatest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator NovaBiotics
- Class Anti-inflammatories; Antibacterials; Antidotes; Hepatoprotectants; Mercaptoethylamines; Mucolytics; Small molecules
- Mechanism of Action Glutathione synthase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Cystic-fibrosis-associated-respiratory-tract-infections in Scotland (Inhalation, Powder)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Cystic-fibrosis-associated-respiratory-tract-infections in United Kingdom (Inhalation, Powder)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Cystic-fibrosis-associated-respiratory-tract-infections in USA (Inhalation, Powder)